CY1111014T1 - Μεθοδος για τη βελτιωση της βιοδιαθεσιμοτητας της οσπεμιφενης - Google Patents

Μεθοδος για τη βελτιωση της βιοδιαθεσιμοτητας της οσπεμιφενης

Info

Publication number
CY1111014T1
CY1111014T1 CY20081100456T CY081100456T CY1111014T1 CY 1111014 T1 CY1111014 T1 CY 1111014T1 CY 20081100456 T CY20081100456 T CY 20081100456T CY 081100456 T CY081100456 T CY 081100456T CY 1111014 T1 CY1111014 T1 CY 1111014T1
Authority
CY
Cyprus
Prior art keywords
improving
odemphenfine
biodiversity
prevention
compound
Prior art date
Application number
CY20081100456T
Other languages
English (en)
Inventor
Markku Anttila
Original Assignee
Hormos Medical Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111014(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd. filed Critical Hormos Medical Ltd.
Publication of CY1111014T1 publication Critical patent/CY1111014T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30Dietetic or nutritional methods, e.g. for losing weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση αυτή σχετίζεται με μία μέθοδο για τη βελτίωση της βιοδιαθεσιμότητας της οσπεμιφένης ή ενός γεωμετρικού ισομερούς, ενός στεροϊσομερούς, ενός φαρμακευτικώς δραστικού άλατος ή ενός εστέρα ή ενός μεταβολίτη της ένωσης αυτής, όπου η εν λόγω ένωση χορηγείται από το στόμα σε συνδυασμό με την πρόσληψη τροφής. Η εφεύρεση σχετίζεται επίσης με τη θεραπευτική αντιμετώπιση ή την πρόληψη της οστεοπόρωσης, της ατροφίας του δέρματος, της ατροφίας των επιθηλίων και των βλεννογόνων, καθώς και με τη θεραπευτική αντιμετώπιση ή την πρόληψη ουρολογικών ή κολπικών συμπτωμάτων.
CY20081100456T 2004-02-13 2008-04-24 Μεθοδος για τη βελτιωση της βιοδιαθεσιμοτητας της οσπεμιφενης CY1111014T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene
EP05701734A EP1713458B1 (en) 2004-02-13 2005-01-14 Method for enhancing the bioavailability of ospemifene

Publications (1)

Publication Number Publication Date
CY1111014T1 true CY1111014T1 (el) 2015-06-11

Family

ID=34837941

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20081100456T CY1111014T1 (el) 2004-02-13 2008-04-24 Μεθοδος για τη βελτιωση της βιοδιαθεσιμοτητας της οσπεμιφενης
CY2015027C CY2015027I1 (el) 2004-02-13 2015-07-08 Μεθοδος για τη βελτιωση της βιοδιαθεσιμοτητας της οσπεμιφενης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2015027C CY2015027I1 (el) 2004-02-13 2015-07-08 Μεθοδος για τη βελτιωση της βιοδιαθεσιμοτητας της οσπεμιφενης

Country Status (21)

Country Link
US (5) US8236861B2 (el)
EP (1) EP1713458B1 (el)
JP (2) JP5577011B2 (el)
CN (1) CN1925847A (el)
AT (1) ATE387910T1 (el)
AU (1) AU2005211958B2 (el)
BR (1) BRPI0507661A (el)
CA (1) CA2556089C (el)
CY (2) CY1111014T1 (el)
DE (1) DE602005005165T2 (el)
DK (1) DK1713458T5 (el)
ES (1) ES2302177T3 (el)
HU (1) HUS1500030I1 (el)
LT (1) LTC1713458I2 (el)
LU (1) LU92736I2 (el)
MX (1) MXPA06009274A (el)
NO (2) NO337656B1 (el)
PL (1) PL1713458T3 (el)
PT (1) PT1713458E (el)
RU (1) RU2385716C2 (el)
WO (1) WO2005077350A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
EP1742618B1 (en) 2004-05-04 2012-08-22 Hormos Medical Ltd. Liquid oral formulations of ospemifene
AU2006339325A1 (en) * 2005-11-09 2007-09-07 Hormos Medical Ltd. Formulations of fispemifene
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
CN101636372B (zh) * 2007-02-14 2013-03-27 霍尔莫斯医疗有限公司 有治疗价值的三苯基丁烯衍生物的制备方法
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-(对-((z-4-氯-1,2-二苯基-1-丁烯基)苯氧基)乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
WO2019217924A1 (en) 2018-05-11 2019-11-14 Xenon Pharmaceuticals Inc. Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
ES2255294T3 (es) * 1998-08-07 2006-06-16 Chiron Corporation Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
US6219674B1 (en) 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
CA2438816A1 (en) 2001-02-22 2002-09-06 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
CA2484542C (en) 2002-06-06 2010-11-02 Hormos Medical Corporation Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US20050187302A1 (en) 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency

Also Published As

Publication number Publication date
EP1713458A1 (en) 2006-10-25
DE602005005165T2 (de) 2009-04-30
CA2556089A1 (en) 2005-08-25
MXPA06009274A (es) 2007-04-16
US20050182143A1 (en) 2005-08-18
AU2005211958B2 (en) 2010-11-25
US8236861B2 (en) 2012-08-07
RU2385716C2 (ru) 2010-04-10
US20160101065A1 (en) 2016-04-14
US20120270952A1 (en) 2012-10-25
JP6023119B2 (ja) 2016-11-09
NO337656B1 (no) 2016-05-23
NO20151603L (no) 2006-11-03
WO2005077350A1 (en) 2005-08-25
US9241915B2 (en) 2016-01-26
RU2006132719A (ru) 2008-03-20
US20130324614A1 (en) 2013-12-05
LTPA2015023I1 (lt) 2015-08-25
NO20063960L (no) 2006-11-03
DK1713458T3 (da) 2008-07-07
CY2015027I2 (el) 2016-04-13
EP1713458B1 (en) 2008-03-05
BRPI0507661A (pt) 2007-07-17
DK1713458T5 (da) 2008-09-29
US20140303259A1 (en) 2014-10-09
CY2015027I1 (el) 2016-04-13
ATE387910T1 (de) 2008-03-15
PT1713458E (pt) 2008-05-07
ES2302177T3 (es) 2008-07-01
US8470890B2 (en) 2013-06-25
CA2556089C (en) 2013-04-02
DE602005005165D1 (de) 2008-04-17
JP2007522190A (ja) 2007-08-09
JP5577011B2 (ja) 2014-08-20
LU92736I2 (fr) 2015-08-10
US9855224B2 (en) 2018-01-02
PL1713458T3 (pl) 2008-08-29
LTC1713458I2 (lt) 2017-06-26
US8772353B2 (en) 2014-07-08
AU2005211958A1 (en) 2005-08-25
CN1925847A (zh) 2007-03-07
JP2014141533A (ja) 2014-08-07
HUS1500030I1 (hu) 2015-08-28
NO339190B1 (no) 2016-11-14

Similar Documents

Publication Publication Date Title
CY1111014T1 (el) Μεθοδος για τη βελτιωση της βιοδιαθεσιμοτητας της οσπεμιφενης
CY1111500T1 (el) Οπιοειδη για τη θεραπεια χρονιας αποφρακτικης πνευμονοπαθειας (copd)
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
DK1814534T3 (da) Derivater af 5-aminolevulinsyre til behandling af acne
CY1111689T1 (el) Στερεες φαρμακοτεχνικες μορφες ospemifene
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
EA201170441A1 (ru) Терапевтические противовирусные пептиды
CY1105787T1 (el) Θepαπευτικη αντιμετωπιση η προληψη της ατροφιας του ουροποιογεννητικου συστηματος και τα συμπτωματα της σε γυναικες
EA200801619A1 (ru) Способ улучшения фармакокинетики ингибиторов интегразы вич (варианты), набор и фармацевтическая композиция (варианты)
CY1112451T1 (el) Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
CY1114791T1 (el) Πιμοβενδανη για χρηση στη θεραπεια της υπερτροφικης μυοκαρδιοπαθειας σε γατες
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
CY1120852T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας
CY1115081T1 (el) Νεο εκχυλισμα απο γαϊδουραγκαθο, μεθοδος για την παρασκευη και η χρηση του
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
CY1118402T1 (el) Η χρηση πηγης l3 και/ή l5 ως εμβολιου ή ως διαγνωστικου για παρασιτικη παθηση
CY1109826T1 (el) Μεθοδοι για την βελτιωση της βιοδιαθεσιμοτητας ενος αναστολεα ρενινης
CY1121280T1 (el) Χρηση της θυαζολοπυριμιδινονης για τη θεραπεια της φλεγμονωδους νοσου του εντερου
DK1765785T3 (da) Prostaglandinanaloger
CY1118581T1 (el) Νεα χρηση για αλφα-συμπαθομιμητικα με δομη 2-ιμιδαζολινης
MX2021008984A (es) Inhibidor jak y metodo de preparacion del mismo.
CY1116514T1 (el) Αναστολεις toy nf-kb
MA34273B1 (fr) Utilisation de la ferroquine dans le traitement ou la prevention du paludisme
Kawasaki Hypertension, mucositis, palmar-plantar erythrodysesthesia syndrome and fatal haemorrhage: case report
CY1118473T1 (el) Η χρηση ενος αναστολεα της αγγειοπεπτιδασης για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης